Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Diabetes
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Diabetes
    Darbepoetin Alfa Risks Outweigh Benefits for Patients With CKD, Diabetes, and Anaemia: Presented at Renal Week 2009 - (DGDispatch)
    Fenofibrate May Protect Diabetics Against Loss of Renal Function: Presented at Renal Week 2009 - (DGDispatch)
    A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease - (N Engl J Med)
    TopAbstracts in Diabetes 11/03/2009 - (DGNews)
    Paricalcitol Added to Hypertension Therapy Lowers Albuminuria in Patients With Diabetes and Chronic Kidney Disease: Presented at Renal Week 2009 - (DGDispatch)

    News archive

     Recent webcasts/CME - Diabetes
    • Optimizing Insulin-Dependent Diabetes Management in Long-Term Care
    • Insulin-Dependent Diabetes in Long-Term Care: Scope of the Problem and Effective Management
    • Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
      Diabetes Management - Pearls of Lipid Control
      Obesity Management in Patients with Type 2 Diabetes

      Webcasts/CME archive

       Recent cases - Diabetes
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        A Patient Presenting with Symptomatic Hypomagnesemia Caused by Metformin-Induced Diarrhoea: A Case Report
        Absence of Diabetic Retinopathy in a Patient who has had Diabetes Mellitus for 69 Years, and Inadequate Glycemic Control: Case Report
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Compound Heterozygous Mutation of Aquaporin 2 Gene in Woman Patient with Congenital Nephrogenic Diabetes Insipidus

        Cases archive
          




        my personal edition > diabetes > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Aspart and Lispro Insulin Identical in Their Pharmacokinetics And Effects on Glucose and Lipid Metabolism

        A DGReview of :"Comparison of Insulin Aspart and Lispro: Pharmacokinetic and metabolic effects"
        Diabetes Care

        07/17/2003
        By Emma Hitt, PhD


        Insulin aspart and lispro appear to produce identical serum insulin levels and are equally effective in correcting carbohydrate and fat metabolism abnormalities in patients with type 1 diabetes, according to the findings of a small observational study.

        Both insulin aspart and lispro are rapidly-acting human insulin analogs, which are being increasingly used. However, it is unclear whether they are interchangeable in clinical practice.

        To compare the two insulins, Carol Homko, PhD, from the Division of Endocrinology/Diabetes/Metabolism at Temple University School of Medicine, in Philadelphia, Pennsylvania, and colleagues studied the effects of insulin aspart and lispro in 7 C-peptide-negative patients with type 1 diabetes.

        Participants' plasma glucose was normalised overnight by intravenous infusion of insulin. The next morning, they received at random subcutaneous injections of either aspart or lispro (mean dose of 9.4 U). The next month the patients returned and received an injection of the other insulin.

        Following the injections, the patients' plasma glucose level was clamped at approximately 5.5 mmol/l for the next 4-5 hours with a variable infusion of 20% glucose. The study was ended after 8 hours.

        Both insulin analogs produced similar serum insulin levels. Thirty minutes after injection, insulin concentrations increased from an average of 39 to 256 pmol/L for insulin aspart and from 43 to 286 pmol/L for insulin lispro (P=0.24). Insulin levels then declined at similar rates in both groups, reaching basal levels approximately 4 hours after injection.

        The two insulins also had similar effects on glucose and fat metabolism. Effects on glucose uptake, glucose oxidation, and endogenous glucose production peaked after about 2 to 3 hours and disappeared after 5 to 6 hours. Effects on lipid metabolism were also similar between the two insulins and peaked at approximately 2 hours and disappeared after about 4 hours.

        "To our knowledge, this is the first study comparing action of lispro and aspart on carbohydrate and fat metabolism in the same patients," Dr. Homko and colleagues note.

        They conclude that while the study size was small, "our data suggested that these two rapidly acting insulin analogs should be equally effective in treating the metabolic abnormalities of patients with type 1 diabetes."
        Diabetes Care 2003;26:7:2027-2031. "Comparison of Insulin Aspart and Lispro: Pharmacokinetic and metabolic effects"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send